ReviewAntibiotics (Basel, Switzerland)2021
Phages for Africa: The Potential Benefit and Challenges of Phage Therapy for the Livestock Sector in Sub-Saharan Africa.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
- Safe Meat, Smart Science: Biotechnology's Role in Antibiotic Residue Removal.Antibiotics (Basel, Switzerland) · 2025Review
- Dual Nature of Bacteriophages: Friends or Foes in Minimally Processed Food Products-A Comprehensive Review.Viruses · 2025Review
- Alternative approaches to antibiotics in the control of mastitis in dairy cows: a review.Veterinary research communications · 2025Review
- Review
- Harnessing Bacteriophages to Combat Antibiotic-Resistant Infections in Africa: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- Assessment of the Nonlinear Electrophoretic Migration of Nanoparticles and Bacteriophages.Micromachines · 2024Article
- NovelPHAGE (New Rochelle, N.Y.) · 2023Article
- Bacteriophage Therapy to Control Bovine Mastitis: A Review.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Alternatives to Antimicrobial Treatment in Bovine Mastitis Therapy: A Review.Antibiotics (Basel, Switzerland) · 2023Review
- Gender-Responsive Design of Bacteriophage Products to Enhance Adoption by Chicken Keepers in Kenya.Viruses · 2023Article
- Formulation of phage cocktails and evaluation of their interaction with antibiotics in inhibiting carbapenemase-producingAfrican journal of laboratory medicine · 2022Article
- Treating bacterial infections with bacteriophages in the 21st century.Southern African journal of infectious diseases · 2022Article
- Prospects of bacteriophage collections in disinfectant applications.Veterinary world · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
One of the world's fastest-growing human populations is in Sub-Saharan Africa (SSA), accounting for more than 950 million people, which is approximately 13% of the global population. Livestock farming is vital to SSA as a source of food supply, employment, and income. With this population increase, meeting this demand and the choice for a greater income and dietary options come at a cost and lead to the spread of zoonotic diseases to humans. To control these diseases, farmers have opted to rely heavily on antibiotics more often to prevent disease than for treatment. The constant use of antibiotics causes a selective pressure to build resistant bacteria resulting in the emergence and spread of multi-drug resistant (MDR) organisms in the environment. This necessitates the use of alternatives such as bacteriophages in curbing zoonotic pathogens. This review covers the underlying problems of antibiotic use and resistance associated with livestock farming in SSA, bacteriophages as a suitable alternative, what attributes contribute to making bacteriophages potentially valuable for SSA and recent research on bacteriophages in Africa. Furthermore, other topics discussed include the creation of phage biobanks and the challenges facing this kind of advancement, and the regulatory aspects of phage development in SSA with a focus on Kenya.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.